Written By: Aashish Vashistha
June 8, 2022 (New Delhi): Giving ‘Happy Tears’ to many patients who have been fighting with the deadly disease of rectal cancer, US Doctors got stunned after seeing the positive results of the trial. Early trials of a drug to treat rectal cancer led to remission in every participant. The trial was very small, with just 12 patients, however, patients and doctors are shocked as well as surprised after seeing the results. This surprising study was published published on Sunday (June 5) in the New England Journal of Medicine. The study is backed by drug maker GlaxoSmithKline.
It was not less than a nightmare or someone reading fiction books full of imaginations that cancer in all the patients presented in the trial vanishes during the US drugs trial. After the successful completion of the trial, it was found that Tumor vanished in all 18 rectal cancer patients. The trial was conducted for the duration of 6 months. The cost of the drug (in trial phase) is approximately Rs 8.55 lakh as per studies.
This study has given hopes to many people who are are victims of this dreadful ‘life taking’ disease. This studies clearly suggests that Cancer can be removed completely without going through long and painful chemotherapy sessions or surgeries. According to The New York Times, the drug — dostarlimab — was administered to 18 rectal cancer patients, who seemed to have recovered completely as the disease could not be detected by physical exam, endoscopy, positron emission tomography (PET) or magnetic resonance imaging (MRI) scans. Much reports are awaited on this big success by the Memorial Sloan Kettering Cancer Center in Manhattan.